NASDAQ:LTGO Latigo Biotherapeutics (LTGO) Stock Price, News & Analysis $24.23 -0.77 (-3.08%) As of 08/28/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and TrendsSEC Filings About Latigo Biotherapeutics Stock (NASDAQ:LTGO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Latigo Biotherapeutics alerts:Sign Up Key Stats Today's Range$24.23▼$25.8150-Day Range N/A52-Week Range$17.22▼$25.93Volume217,741 shsAverage Volume423,531 shsMarket Capitalization$1.53 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc. is based in THOUSAND OAKS, Calif. Read More Receive LTGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Latigo Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTGO Stock News HeadlinesLatigo Biotherapeutics Inc.August 15, 2026 | barrons.comInside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes PublicAugust 13, 2026 | 247wallst.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 30 at 1:00 AM | Porter & Company (Ad)Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes PublicAugust 13, 2026 | 247wallst.comForesite Capital Management V, Acquires 140,000 Shares of Latigo Biotherapeutics (NASDAQ:LTGO) StockAugust 11, 2026 | insidertrades.comLatigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right ValuedAugust 10, 2026 | finance.yahoo.comLatigo Biotherapeutics Commences IPO Process For Pain Treatment PipelineJuly 28, 2026 | seekingalpha.comSee More Headlines LTGO Stock Analysis - Frequently Asked Questions How have LTGO shares performed this year? Latigo Biotherapeutics' stock was trading at $18.25 on August 7, 2026. Since then, LTGO shares have increased by 32.8% and is now trading at $24.23. When did Latigo Biotherapeutics IPO? Latigo Biotherapeutics (LTGO) raised $326 million in an IPO on Friday, August 7th 2026. The company issued 19,200,000 shares at a price of $16.00-$18.00 per share. When does Latigo Biotherapeutics' quiet period expire? Latigo Biotherapeutics's quiet period expires on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its initial public offering on August 7th. The total size of the offering was $345,600,000 based on an initial share price of $18.00. During Latigo Biotherapeutics' quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Latigo Biotherapeutics? Shares of LTGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:LTGO CIK2056611 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares63,240,000Free FloatN/AMarket Cap$1.53 billion OptionableN/A BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LTGO) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredHe called Apple then saw 12,000%+ gains. Now he's pointing at THIS.In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Latigo Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Latigo Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
